LMP1 acts as a constitutively active tumour necrosis factor (TNF) receptor, activating a plethora of mitogenic signalling pathways that are frequently dysregulated in many human cancers, including both the canonical and non-canonical NF-κB pathways, the mitogenic ERK-MAPK and p38-MAPK pathways, the pro-survival PI3K/Akt pathway, the stress-related JNK/SAPK pathway, as well as the Smad-independent activin A/TGFβ signalling cascades, which may contribute to the fibrotic response that drives carcinoma growth and metastases [8,9]. Here, PDLIM7 is linked to cancer.